Scribe Therapeutics Inc. (SCTX)

NASDAQ: SCTX · Real-Time Price · USD

20.40

+2.04 (11.11%)

At close: Jul 30, 2026, 4:00 PM EDT

22.00

+1.60 (7.84%)

Pre-market: Jul 31, 2026, 7:17 AM EDT

Scribe Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	36.28	51.17	27.41
Revenue Growth	-	86.68%	-
Gross Profit	-19.83	-9.62	-29.67
Operating Income	-32.94	-26.07	-42.83
Net Income	-35.73	-21.81	-47.79
Earnings Per Share	-14.64	-8.98	-19.94
EPS Growth	-	-	-

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	49.73	57.96	105.17
Total Debt	46.33	41.43	41.68
Net Cash (Debt)	3.4	16.54	63.49
Net Cash Growth	-	-73.96%	-
Net Cash Per Share	1.39	6.81	26.50

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-39.15	-45.21	-45.24
Capital Expenditures	-0.8	-1.27	-1.35
Free Cash Flow	-39.94	-46.48	-46.58
Free Cash Flow Growth	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	-54.65%	-18.80%	-108.22%
Operating Margin	-90.79%	-50.94%	-156.24%
Pretax Margin	-101.95%	-46.14%	-137.02%
Profit Margin	-98.48%	-42.61%	-174.32%
FCF Margin	-110.09%	-90.83%	-169.93%